The DOI matches its Crossref record.
GroupBuild: a fragment-based method for de novo drug design
Abstract
A novel method for de novo drug design, GroupBuild, has been developed to suggest chemically reasonable structures which fill the active sites of enzymes. The proposed molecules provide good steric and electrostatic contact with the enzyme and exist in low-energy conformations. These structures are composed entirely of individual functional groups (also known as "building blocks" or "fragments") which the program chooses from a predefined library. User-selected enzyme seed atom(s) may be used to determine the area(s) in which structure generation begins. Alternatively, GroupBuild may begin with a predocked "inhibitor core" from which fragments are grown. For each new fragment generated by the program, several thousand candidates in a variety of locations and orientations are considered. Each of these candidates is scored based on a standard molecular mechanics potential function. The selected fragment and orientation are chosen from among the highest scoring cases. Tests of the method using HIV protease, FK506 binding protein, and human carbonic anhydrase demonstrate that structures similar to known potent inhibitors may be generated with GroupBuild.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Docking and scoring in virtual screening for drug discovery: methods and applications
Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1549 · Cited by 4,150
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Software for molecular docking: a review
Pagadala, N. S., Syed, K., & Tuszynski, J. (2017) · Biophysical Reviews · doi:10.1007/s12551-016-0247-1 · Cited by 1,522
B�hm, H.-J. (1994) · Journal of Computer-Aided Molecular Design · doi:10.1007/bf00126743 · Cited by 1,011
Computer-based de novo design of drug-like molecules
Schneider, G., & Fechner, U. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1799 · Cited by 948
The Process of Structure-Based Drug Design
Anderson, A. C. (2003) · Chemistry & Biology · doi:10.1016/j.chembiol.2003.09.002 · Cited by 939
INHIBITORS OF HIV-1 PROTEASE: A Major Success of Structure-Assisted Drug Design
Wlodawer, A., & Vondrasek, J. (1998) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.27.1.249 · Cited by 734
A review of protein-small molecule docking methods
Taylor, R. D., Jewsbury, P. J., & Essex, J. W. (2002) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1020155510718 · Cited by 655
Ligand binding affinity prediction by linear interaction energy methods
Hansson, T., Marelius, J., & Åqvist, J. (1998) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1007930623000 · Cited by 459
Böhm, H.-J. (1998) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1007999920146 · Cited by 431
Virtual screening and fast automated docking methods
Schneider, G., & Böhm, H.-J. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(01)02091-8 · Cited by 404
High-throughput docking for lead generation
Abagyan, R., & Totrov, M. (2001) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00217-9 · Cited by 343
Heteroaromatic Rings of the Future
Pitt, W. R., Parry, D. M., Perry, B. G., & Groom, C. R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801513z · Cited by 332
Structure-based drug design: progress, results and challenges
Verlinde, C. L., & Hol, W. G. (1994) · Structure · doi:10.1016/s0969-2126(00)00060-5 · Cited by 331
Böhm, H., & Klebe, G. (1996) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199625881 · Cited by 328
4-Aminoquinolines—Past, present, and future; A chemical perspective
O'Neill, P. M., Bray, P. G., Hawley, S. R., Ward, S. A., & Park, B. K. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00084-3 · Cited by 282
Flexible ligand docking using a genetic algorithm
Oshiro, C. M., Kuntz, I. D., & Dixon, J. S. (1995) · Journal of Computer-Aided Molecular Design · doi:10.1007/bf00124402 · Cited by 275
Structure-based drug design with geometric deep learning
Isert, C., Atz, K., & Schneider, G. (2023) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2023.102548 · Cited by 182
Fragment Informatics and Computational Fragment‐Based Drug Design: An Overview and Update
Sheng, C., & Zhang, W. (2013) · Medicinal Research Reviews · doi:10.1002/med.21255 · Cited by 80
Metadata
- Authors
- Rotstein, S. H., & Murcko, M. A.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1993-06
- Volume
- 36
- Issue
- 12
- Pages
- 1700-1710
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2047819524
- Cited by
- 192
- References
- 0
- FWCI
- 22.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.